Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…Abstract Number: 2215 • 2019 ACR/ARP Annual Meeting
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…Abstract Number: 1872 • 2019 ACR/ARP Annual Meeting
Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014
Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected…Abstract Number: 2216 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
Background/Purpose: Bone mineral density (BMD) is used for the diagnosis of osteoporosis, predicting future fracture risk, and monitoring osteoporosis treatment. Osteoporosis is defined as BMD…Abstract Number: 1873 • 2019 ACR/ARP Annual Meeting
Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Background/Purpose: The morbidity and mortality of osteoporotic fractures threaten our aging population. Despite advances in new therapies for osteoporosis and technology to more effectively communicate, fewer…Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Background/Purpose: Osteoporosis (OP) is a problem in the aging population. Patients with autoimmune disease are at increased risk for OP given their history of steroid…Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…Abstract Number: 1929 • 2019 ACR/ARP Annual Meeting
Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Background/Purpose: The pathogenesis of osteoporosis, a common disease with high morbidity1, comprises genetic and environmental factors2. Recent studies demonstrated that blood samples are a source…Abstract Number: 2221 • 2019 ACR/ARP Annual Meeting
Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Background/Purpose: Data on prevention of fractures after heart transplant (HTx) are controversial in the literature. Understanding the effects of HTx on bone may guide appropriate…Abstract Number: 2323 • 2018 ACR/ARHP Annual Meeting
Predictors of Mortality in Patients with Hip Fragility Fracture
Background/Purpose: In Osteoporosis, hip fractures account for significant disease burden, with increased morbi-mortality and financial load on the patient and healthcare system. This study aimed…Abstract Number: 2326 • 2018 ACR/ARHP Annual Meeting
Outcomes One Year after Hip Fracture Repair in the Elderly: Does Social Isolation Matter?
Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over age 65. Social isolation—how integrated a patient…Abstract Number: 2336 • 2018 ACR/ARHP Annual Meeting
Identification of Osteoporosis As a Reason for Vertebral Fractures in Patients with Rheumatoid Arthritis and Non-Inflammatory Musculoskeletal Diseases – a Comparison between Trabecular Bone Score (TBS) and Bone Mineral Density (BMD)
Identification of osteoporosis as a reason for vertebral fractures in patients with rheumatoid arthritis and non-inflammatory musculoskeletal diseases – A comparison between trabecular bone score…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 20
- Next Page »